ClariVest Asset Management’s Fortress Biotech FBIO Stock Holding History

ClariVest Asset Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,248	Closed	-$369K	–	744
2018 Q2	$369K	Buy	8,248 +73	+0.9%	+$4.11K	0.01%	533
2018 Q1	$558K	Buy	8,175 +194	+2%	+$12.3K	0.01%	491
2017 Q4	$477K	Hold	7,981	–	–	0.01%	493
2017 Q3	$529K	Buy	7,981 +60	+0.8%	+$4.04K	0.01%	384
2017 Q2	$564K	Sell	7,921 -2,847	-26%	-$168K	0.01%	378
2017 Q1	$598K	Buy	10,768 +107	+1%	+$4.79K	0.02%	379
2016 Q4	$432K	Buy	10,661 +2,700	+34%	+$101K	0.01%	412
2016 Q3	$355K	Buy	7,961 +113	+1%	+$4.81K	0.01%	425
2016 Q2	$316K	Buy	7,848 +2,740	+54%	+$128K	0.01%	415
2016 Q1	$238K	Buy	5,108 +53	+1%	+$2.24K	0.01%	448
2015 Q4	$212K	Buy	5,055 +848	+20%	+$35.5K	0.01%	450
2015 Q3	$164K	Buy	4,207 +27	+0.6%	+$1.26K	﹤0.01%	439
2015 Q2	$211K	Buy	+4,180	New	+$215K	0.01%	407

Other funds holding FBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

ClariVest Asset Management's FBIO Position: Q3 2018 in Review

ClariVest Asset Management sold out of Fortress Biotech (FBIO) in Q3 2018, closing a stake of 8,248 shares — an estimated $369K sold.

ClariVest Asset Management first reported a position in FBIO in Q2 2015 and held it in 13 quarters. The position peaked at $598K in Q1 2017. 65 funds tracked by Wall St. Rank hold FBIO as of Q3 2018.

ClariVest Asset Management reported no remaining Fortress Biotech position as of Q3 2018 after selling out during the quarter.
ClariVest Asset Management sold 8,248 Fortress Biotech shares in Q3 2018, an estimated $369K.
ClariVest Asset Management first reported a position in Fortress Biotech in Q2 2015 and held it in 13 quarters.
ClariVest Asset Management's Fortress Biotech position peaked at $598K in Q1 2017.
65 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2018.

Based on ClariVest Asset Management's 13F filing for Q3 2018, filed 7 Nov 2018.